New pill combo aims to crush bad cholesterol

NCT ID NCT07218900

Ongoing Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a new drug called AZD0780 to the common statin rosuvastatin can lower 'bad' LDL cholesterol more than rosuvastatin alone. About 76 adults with high cholesterol will take either AZD0780 or a placebo pill, plus rosuvastatin, for 12 weeks. Neither participants nor doctors know who gets the real drug until the study ends.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: AZD0780 (a small molecule drug taken as a tablet) combined with rosuvastatin (a statin tablet)
What this could lead to: If it works, this could lead to a new combination treatment that lowers 'bad' cholesterol more effectively than statins alone.
What could go wrong: This is an early Phase 2 trial with only 76 people, so results may not apply to everyone. The drug may not lower cholesterol enough or could have side effects not yet seen.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DYSLIPIDAEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Dyslipidemias inherited lipid metabolism disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DYSLIPIDAEMIA

Contacts and locations

Locations

Research Site

Aramil, 624002, Russia
Research Site

Ivanovo, 153012, Russia
Research Site

Moscow, 105554, Russia
Research Site

Moscow, 111539, Russia
Research Site

Moscow, 117292, Russia
Research Site

Moscow, 121552, Russia
Research Site

Perm, 614000, Russia
Research Site

Saint Petersburg, 194156, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.